Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.

Bjørnstad R, Aesoy R, Bruserud Ø, Brenner AK, Giraud F, Dowling TH, Gausdal G, Moreau P, Døskeland SO, Anizon F, Herfindal L.

Mol Cancer Ther. 2019 Mar;18(3):567-578. doi: 10.1158/1535-7163.MCT-17-1234. Epub 2019 Jan 24.

PMID:
30679386
2.

The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome.

Brenner AK, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Grønningsæter IS, Bartaula-Brevik S, Bruserud Ø.

Cancers (Basel). 2019 Jan 10;11(1). pii: E73. doi: 10.3390/cancers11010073.

3.

Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators.

Aasebø E, Hernandez-Valladares M, Selheim F, Berven FS, Brenner AK, Bruserud Ø.

Proteomes. 2018 Dec 20;7(1). pii: E1. doi: 10.3390/proteomes7010001.

4.

S100 Proteins in Acute Myeloid Leukemia.

Brenner AK, Bruserud Ø.

Neoplasia. 2018 Dec;20(12):1175-1186. doi: 10.1016/j.neo.2018.09.007. Epub 2018 Oct 23. Review.

5.

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.

Tvedt THA, Melve GK, Tsykunova G, Ahmed AB, Brenner AK, Bruserud Ø.

Int J Mol Sci. 2018 Sep 22;19(10). pii: E2886. doi: 10.3390/ijms19102886.

6.

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.

Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2018 Jul;22(7):639-653. doi: 10.1080/14728222.2018.1487401. Epub 2018 Jun 22.

PMID:
29889583
7.

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.

Nepstad I, Reikvam H, Brenner AK, Bruserud Ø, Hatfield KJ.

Int J Mol Sci. 2018 Jan 27;19(2). pii: E382. doi: 10.3390/ijms19020382.

8.

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.

Johansen S, Brenner AK, Bartaula-Brevik S, Reikvam H, Bruserud Ø.

Int J Mol Sci. 2018 Jan 15;19(1). pii: E251. doi: 10.3390/ijms19010251. Review.

9.

The constitutive protease release by primary human acute myeloid leukemia cells.

Honnemyr M, Bruserud Ø, Brenner AK.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1985-1998. doi: 10.1007/s00432-017-2458-7. Epub 2017 Jun 19.

PMID:
28631213
10.

CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.

Brenner AK, Reikvam H, Rye KP, Hagen KM, Lavecchia A, Bruserud Ø.

Molecules. 2017 Mar 11;22(3). pii: E446. doi: 10.3390/molecules22030446.

11.

Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.

Brenner AK, Tvedt TH, Nepstad I, Rye KP, Hagen KM, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2017 Apr;21(4):357-369. doi: 10.1080/14728222.2017.1300255. Epub 2017 Mar 3.

PMID:
28281897
12.

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms.

Brenner AK, Nepstad I, Bruserud Ø.

Front Immunol. 2017 Feb 9;8:106. doi: 10.3389/fimmu.2017.00106. eCollection 2017.

14.

Rethinking the role of osteopontin in human acute myeloid leukemia.

Brenner AK, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Bruserud Ø.

Leuk Lymphoma. 2017 Jun;58(6):1494-1497. doi: 10.1080/10428194.2016.1243682. Epub 2016 Oct 14. No abstract available.

PMID:
27739925
15.

The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.

Kittang AO, Sand K, Brenner AK, Rye KP, Bruserud Ø.

Int J Mol Sci. 2016 Jul 5;17(7). pii: E1080. doi: 10.3390/ijms17071080.

16.
17.

The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells.

Reikvam H, Brenner AK, Hagen KM, Liseth K, Skrede S, Hatfield KJ, Bruserud Ø.

Stem Cell Res. 2015 Nov;15(3):530-541. doi: 10.1016/j.scr.2015.09.008. Epub 2015 Sep 25.

18.

Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.

Ersvaer E, Brenner AK, Vetås K, Reikvam H, Bruserud Ø.

BMC Pharmacol Toxicol. 2015 May 2;16:12. doi: 10.1186/s40360-015-0012-2.

19.

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.

Reikvam H, Hauge M, Brenner AK, Hatfield KJ, Bruserud Ø.

Expert Rev Hematol. 2015 Jun;8(3):299-313. doi: 10.1586/17474086.2015.1032935. Epub 2015 Apr 3. Review.

PMID:
25835070
20.

The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers--a comparative study of serum versus plasma samples.

Tvedt TH, Rye KP, Reikvam H, Brenner AK, Bruserud Ø.

J Immunol Methods. 2015 Mar;418:19-28. doi: 10.1016/j.jim.2015.01.006. Epub 2015 Jan 28.

PMID:
25637409
21.

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.

Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT, Pendino F.

Oncotarget. 2015 Feb 20;6(5):2794-811.

22.
23.

Using MUSIC and CC(CO)NH for backbone assignment of two medium-sized proteins not fully accessible to standard 3D NMR.

Brenner AK, Frøystein NÅ.

Molecules. 2014 Jun 26;19(7):8890-903. doi: 10.3390/molecules19078890.

24.

Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?

Reikvam H, Brenner AK, Nepstad I, Sulen A, Bruserud Ø.

Expert Opin Ther Targets. 2014 Aug;18(8):929-44. doi: 10.1517/14728222.2014.924925. Epub 2014 Jun 24. Review.

PMID:
24956934
25.

Thermal stability of chicken brain α-spectrin repeat 17: a spectroscopic study.

Brenner AK, Kieffer B, Travé G, Frøystein NA, Raae AJ.

J Biomol NMR. 2012 Jun;53(2):71-83. doi: 10.1007/s10858-012-9620-y. Epub 2012 May 9.

PMID:
22569754
26.

Human protein N-terminal acetyltransferase hNaa50p (hNAT5/hSAN) follows ordered sequential catalytic mechanism: combined kinetic and NMR study.

Evjenth RH, Brenner AK, Thompson PR, Arnesen T, Frøystein NÅ, Lillehaug JR.

J Biol Chem. 2012 Mar 23;287(13):10081-8. doi: 10.1074/jbc.M111.326587. Epub 2012 Feb 6.

27.

Improved activation of lumbar multifidus following spinal manipulation: a case report applying rehabilitative ultrasound imaging.

Brenner AK, Gill NW, Buscema CJ, Kiesel K.

J Orthop Sports Phys Ther. 2007 Oct;37(10):613-9.

PMID:
17970408
28.

The effect and safety of short-term creatine supplementation on performance of push-ups.

Armentano MJ, Brenner AK, Hedman TL, Solomon ZT, Chavez J, Kemper GB, Salzberg D, Battafarano DF, Christie DS.

Mil Med. 2007 Mar;172(3):312-7.

PMID:
17436778

Supplemental Content

Loading ...
Support Center